Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ACRX and SSH stocks are on a roll right now. Two of the hottest stocks out there.
ACRX has EU approval and working on FDA approval next
SSH is working on their FDA Approval
In a research note issued to investors, Michael Higgins at Roth Capital Reiterated their Buy rating on AcelRx Pharmaceuticals Inc (NASDAQ:ACRX). The analyst placed a $7.50 price target on the stock which indicates a 83.82% upside to the last closing price. In the year following Higgins’s ratings, the stocks covered yield an average return of 1.50% according to TipRanks.com. In the past year 5 out of 14 recommendations or 36.00% were successful.
In looking at the consensus numbers, the sell-side analysts covering the stock have a mean target price of $6.5 for AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). This number is the mean estimate from the 6 research brokerages that recently issued reports on the firm.
According to Wall Street, AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) is expected to report earnings per share for the current fiscal quarter of $-0.26. This is the consensus mean estimate based on the individual covering sell-side analysts’ reported numbers. The company last reported earnings for the period ending on 2015-03-31 of $-0.27.
The average recommendation is the arithmetical average of the individual analyst ratings contributed by sell-side research to produce a Consensus Analyst Rating for each stock. On a scale of 1 to 5 where 1 represents a Strong Buy and 5 represents a Strong Sell, has the equity is ranked 2.57 based on 6 broker recommendations. Of the 6 analyst estimates, the most bullish sees the stock reaching $14 within the next 12 months while the most bearish analyst sees the stock at $3 within the year.
Taking a look at the long term growth prospects of the company, sell-side analysts have a consensus mean earnings per share estimate for the current year of $N/A. The high end estimate for this time frame is $N/A with the low being $N/A.
AcelRx Pharmaceuticals, Inc. is a United States-based Pharmaceutical Company, which develops and commercializes therapies for the treatment of pain. The Company’s products include ARX-01 Sufentanil NanoTab PCA System, to solve the problems associated with post-operative intravenous patient-controlled analgesia (IV PCA); ARX-02 Sufentanil NanoTab BTP Management System is a treatment option for cancer patients who suffer from breakthrough pain (BTP). ARX-03 Sufentanil/Triazolam NanoTab, provides non-invasive mild sedation, anxiety reduction and pain relief; and ARX-04 Sufentanil Acute Pain NanoTab, is a sublingual sufentanil product candidate designed to provide a non-invasive, fast-onset treatment of patients with moderate-to-severe acute pain, both on the battlefield and in civilian settings of trauma or injury.
REDWOOD CITY, Calif., July 29, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release Second Quarter financial results after market close on Monday, Aug 3rd, 2015. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on Aug 3rd, 2015 to discuss the financial results and provide a corporate update.
Investors who wish to participate in the conference call may do so by dialing (866) 361-2335 for domestic callers, (855) 669-9657 for Canadian callers or (412) 902-4204 for international callers. Those interested in listening to the conference call live via the internet may do so by visiting the Investors page of the company's website at www.acelrx.com and clicking on the webcast link on the Investors home page.
A webcast replay will be available on the AcelRx website for 90 days following the call by visiting the Investor page of the company's website at www.acelrx.com.
EU approved, Upgraded in rating. ACRX seems to be on the right track. Next task is getting FDA approval. That should be done, as they see EU is on the track track.
DEN PRAIRIE, Minn., July 23, 2015 (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (NASDAQ:SSH) announced today an update on its COUNTER HF™ US pivotal study for the C-Pulse Heart Assist System. COUNTER HF is a prospective, randomized, multi-center, controlled study evaluating the safety and efficacy of the C-Pulse system for the treatment of NYHA Class III and ambulatory Class IV heart failure. The study was temporarily paused this past March after the Company notified the FDA of four deaths in the treatment arm of the study. The deaths were adjudicated as not device or therapy related and as previously announced on May 26th, the FDA approved resumption of patient enrollment in the study.“I’m pleased with the enthusiasm and speed at which sites are being reactivated. We witnessed genuine excitement for the study at our recent investigator meeting and are strongly encouraged by the momentum generated at many of our sites,” commented Dave Rosa, President and Chief Executive Officer of Sunshine Heart.Immediately following the FDA’s decision to approve enrollment to continue the COUNTER HF’s study, Sunshine Heart distributed material to all sites with the necessary documentation in order to achieve site Investigational Review Board (IRB) approvals. Currently, 12 sites have been reactivated which is approximately half of all previously activated sites. Sunshine Heart expects the majority of sites to be reactivated by the end August. In addition, the Company is pleased to announce the enrollment of its first two patients since the resumption of the COUNTER HF study. One of these patients was already reviewed by Sunshine Heart’s newly formed Physician Subject Selection Committee. This process was handled efficiently and led to the first implant being scheduled for this morning.About the COUNTER HF StudyCOUNTER HF is a prospective, randomized, multi-center clinical study. It is being conducted by heart failure and cardiac surgeon specialists in the United States. It is expected to randomize 388 patients in up to 40 clinical sites. The purpose of the study is to determine whether the C-Pulse System is a safe and effective treatment for heart failure patients who meet the following key study qualifications:NYHA Class III or early Class IV heart failure*;Ejection fraction = 35% (measure of how well the heart pumps blood);Taking appropriate heart failure medications as prescribed by doctor; andHave been evaluated for cardiac resynchronization therapy with or without defibrillation (CRT, CRT-D) or implantable cardioverter defibrillator (ICD) therapy.*New York Heart Class (NYHA) Class III or early Class IV: Very limited in daily activities or unable to do activities without discomfort. Become tired, short of breath, and have heart palpitations during physical activity. Note: Other qualifications apply and study doctors will determine who is eligible for the study.About the C-Pulse® Heart Assist SystemThe C-Pulse Heart Assist System, or C-Pulse System, an investigational device in the United States, Canada and countries that do not recognize the CE mark approval, utilizes the scientific principles of intra-aortic balloon counter-pulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. Combined, these potential benefits may help sustain the patient’s current condition or, in some cases, reverse the heart failure process, thereby potentially preventing the need for later-stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. It may also provide relief from the symptoms of Class III and ambulatory Class IV heart failure and improve quality of life and cardiac function. Based on the results from our feasibility study, we also believe that some patients treated with our C-Pulse System may be able to stop using the device due to sustained improvement in their conditions as a result of the therapy.
Caution: Investigational device, limited by Federal (or United States) Law to Investigational use.Sunshine Heart, Inc. (Nasdaq:SSH) is an early-stage medical device company focused on developing, manufacturing and commercializing the C-Pulse System for treatment of Class III and ambulatory Class IV heart failure. Sunshine Heart has completed an approved U.S. Food and Drug Administration (FDA) feasibility clinical study of the C-Pulse System and presented the results in November 2011. In March 2012, the FDA notified the Company that it could move forward with an investigational device exemption (IDE) application. Sunshine Heart received unconditional approval from the FDA in November 2012 to initiate its pivotal study. In July 2012, Sunshine Heart received CE Mark approval for its C-Pulse System in Europe. Sunshine Heart is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The Company has been listed on the NASDAQ Capital Market since February 2012.For further information, please contact:
Investor:
Candice Knoll
Blueprint Life Science Group
T: +1-415-375-3340 Ext. 105
Claudia Drayton
Chief Financial Officer
Sunshine Heart, Inc.
T: +1-952-345-4200
Media:
David Schull
Russo Partners
T: +1-212-845-4271
Christopher Hippolyte
Russo Partners
T: + 1-646-942-5634
Source: Globenewswire Public
Sunshine Heart, Inc.
SSH 0.47%
announced today an update on its COUNTER HF US pivotal study for the C-Pulse Heart Assist System. COUNTER HF is a prospective, randomized, multi-center, controlled study evaluating the safety and efficacy of the C-Pulse system for the treatment of NYHA Class III and ambulatory Class IV heart failure. The study was temporarily paused this past March after the Company notified the FDA of four deaths in the treatment arm of the study. The deaths were adjudicated as not device or therapy related and as previously announced on May 26th, the FDA approved resumption of patient enrollment in the study.
"I'm pleased with the enthusiasm and speed at which sites are being reactivated. We witnessed genuine excitement for the study at our recent investigator meeting and are strongly encouraged by the momentum generated at many of our sites," commented Dave Rosa, President and Chief Executive Officer of Sunshine Heart.
Immediately following the FDA's decision to approve enrollment to continue the COUNTER HF's study, Sunshine Heart distributed material to all sites with the necessary documentation in order to achieve site Investigational Review Board (IRB) approvals. Currently, 12 sites have been
Read more: http://www.benzinga.com/news/15/07/5696283/sunshine-heart-provides-update-on-counter-hf-us-pivotal-study-for-c-pulse-heart-a#ixzz3gk15jwsE
I hear that ICAD and SSH are competitors?
I'm not too much familiar with ICAD but I hear that SSH has 5 upgrades and is going through FDA approval right now. I also see a new PR from SSH.
Can you please let me know about ICAD?
This company seems like a good deal. They're still trading, but you have to call your broker to place the BID and sell.
I think over time this company will have another run up and get bought out.
They've post a little while ago, a new management for this company too.
For this price, what can go wrong putting a few bucks into it.
SSH is a hot stock with their recent 5 upgrades and FDA approval in the process. If anyone is interested to make some good money, while waiting for CEMP.
If anyone is interested in a great stock to invest in, they should check out SSH as they've several upgrades and they're working on their FDA approval.
I just wanted to start a friendly discussion between SSH and THOR. I came here, as Yahoo Message board is full of false information. SSH stock has been upgraded and their working on FDA approval but Scot Trade lists Thor as a competitor of SSH. I was just wondering what is THOR working on? I don't see anything new in the news regarding it.
SSH is working on obtaining their FDA Approval. I can't wait till that happens as it will push the stock upwards to the $50 a share range.
ACRX is doing great right now. They have FDA approval in works, EU approval in works and they've been upgraded. I think this would be a strong buy.
Yes!! finally a good day in the market. All my stocks are doing good. INO is doing good. ACRX and SSH are doing great right now. I can't wait for ACRX and SSH to finish their FDA Approval.
Have a great day everyone!
Another down day for INO. What is going on with this stock? Down for a few days now.
I'm going to wait on buying INO and hold on to my ACRX and SSH Stocks.
Once FDA approval hits both of them, then over $50 both ACRX and SSH Go.
Hopefully things would turn around for INO.
Sorry guys, I sold and move on today. I don't see these gains going on for any longer. I'm reading more and more regarding OVIT and the possibility that it might be a pump and dump scheme.
I'm going to stick with my ACRX and SSH Stocks, as they're both in the process of obtaining FDA approval. Once those hit, it should be in the north of $50 per share.
Hi..
I was debating to buy ADXS shares or more of either ACRX or SSH Stock.
I'm not too sure, which way to go.
ACRX and SSH are working on their FDA approval and then once approved, the stock will go over $50 a share.
Not to sure if ADXS ever got FDA approval or is in process. Debating which way to go.
Seems like another down day of investments for my stocks. :(
Well hopefully I get some good news here soon on my ACRX and SSH Stocks, in regards to their FDA approvals. IF approved, both stocks have a good chance of hitting over $50 a share.
Not sure what's happening with my INO stock.
Come on good news!!
Seems like the market is down. Hopefully picks up soon. Out of my 3 stocks, INO is down and my ACRX and SSH stocks are up. Hopefully there's good news in the tomorrow. Take care. I'm logging out for today!
OVIT is nothing but a pump and dump. There's no financials, no website. Nothing about the company. Only thing that they have is 3rd party news articles. Nothing solid. Sell and get out while you can!